Core Viewpoint - Corning Pharmaceutical-B (09966) has entered into a technology development contract with its wholly-owned subsidiary Jiangsu Corning Pharmaceutical and Suzhou Corning Pharmaceutical, aimed at enhancing the development and production processes of its bispecific antibody-drug conjugate (ADC) candidates [1] Group 1 - Jiangsu Corning Pharmaceutical has commissioned Suzhou Corning Pharmaceutical to provide technical development services, including the development of production processes and analytical methods for ADC candidates [1] - The contract includes the preparation of samples for toxicology studies and the development of clinical trial samples for IND submission, as well as quality and stability studies of related samples [1] - Suzhou Corning Pharmaceutical has extensive experience and competitiveness in process optimization services, having been a reliable service provider for the company since 2018, which enhances familiarity with the company's needs [1] Group 2 - The company believes that the quality of services provided by Suzhou Corning Pharmaceutical, along with the convenience and confidentiality of future technology transfers, will optimize existing production and R&D processes [1] - The competitive pricing of the services compared to other independent third-party suppliers is expected to lower related costs and positively impact the company's product development, manufacturing, and IND applications in the foreseeable future [1]
康宁杰瑞制药-B与苏州康宁杰瑞订立一份技术开发合同